Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Gains from Investment Securities (2023 - 2024)

Sagimet Biosciences has reported Gains from Investment Securities over the past 2 years, most recently at $49000.0 for Q4 2024.

  • Quarterly results put Gains from Investment Securities at $49000.0 for Q4 2024, up 147.12% from a year ago — trailing twelve months through Dec 2024 was -$60000.0 (up 43.93% YoY), and the annual figure for FY2025 was $152000.0, up 2.01%.
  • Gains from Investment Securities for Q4 2024 was $49000.0 at Sagimet Biosciences, down from $4.3 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for SGMT hit a ceiling of $4.5 million in Q2 2024 and a floor of -$104000.0 in Q4 2023.